Biopharma | June 26, 2026
Moderna outlines aggressive multi-modal growth strategy
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
Partnership with Sunshine Healthcare aims to build local pharmaceutical capabilities and strengthen supply chain resilience
Acquisition strengthens Merck's life sciences portfolio, expands capabilities across research and biopharma manufacturing
The company plans to use this funding to boost AI capabilities, expand vernacular content ecosystem, accelerate product development, and scale user acquisition across Tier 2 and Tier 3 markets
This makes the company among few in India to offer fully integrated, end-to-end ADC drug substance development and manufacturing, encompassing payload synthesis, linker development and manufacturing
Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
34% of pharma firms have already deployed function-specific AI, with drug discovery, clinical trials, and medical writing emerging as key high-impact use cases
As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
With this commissioning, Shilpa Medicare joins a very small group of Indian companies capable of offering end-to-end ADC Drug Substance development and manufacturing
Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
Subscribe To Our Newsletter & Stay Updated
